OraSure Technologies, Inc. will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The company will hold a quarterly conference call to discuss the results at 5 p.m. Eastern Time on the same day. Investors can access the webcast via the investor relations page of OraSure’s website, with registration required at least 10 minutes prior to the call.

The webcast will be archived on OraSure’s website shortly after the call concludes and will remain accessible for approximately one year. OraSure Technologies, Inc., along with its wholly-owned subsidiaries DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., specializes in rapid diagnostic tests and sample collection solutions.

Key Event Details

OraSure’s portfolio includes products designed for clinical laboratories, hospitals, physicians’ offices, and public health organizations, among others. The company focuses on decentralizing diagnostics to improve healthcare access and quality.

OraSure Technologies, Inc. announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The authorization permits use with whole blood in live patients and cadaveric oral fluid from individuals suspected of having Ebola disease. This diagnostic tool is critical as the world confronts a serious outbreak in Central Africa, particularly involving the Bundibugyo virus for which no approved vaccine exists.

The OraQuick Ebola 2.0 Rapid Antigen Test is a single-use, qualitative immunoassay designed to detect antigens from viruses within the Orthoebolavirus genus. It can identify all four Ebola viruses currently known to cause disease in humans: Bundibugyo, Zaire, Sudan, and Taï Forest. Results are available directly on the test device in 30 minutes without the need for instruments, batteries, smartphones, or laboratory analysis.

Key Features of the OraQuick Ebola 2.0 Test

The second-generation test offers several improvements over the original version, which received De Novo marketing authorization in 2019. The new test was developed in cooperation with the Biomedical Advanced Research and Development Authority (BARDA) under a contract granted in 2022.

Carrie Eglinton Manner, President and CEO of OraSure, emphasized the importance of the diagnostic tool amid the current epidemic centered in the Democratic Republic of the Congo. The outbreak has extended into neighboring Uganda and resulted in hundreds of deaths, prompting the World Health Organization to declare a global public health emergency. OraSure is ramping up production to meet potential demand and expand access to the test.